ARRIVENT BIOPHARMA, INC. (AVBP)

Import this data to Google Sheets with:

=jivedata("AVBP","financials")

Full statements spill as a table. For one cell: =jivedata("AVBP","Revenue") or =jivedata("AVBP","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

ARRIVENT BIOPHARMA, INC.

AVBP • CIK 0001868279

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Research and Development Expense	$79,004	$153,351	$144,299
General and Administrative Expense	$15,304	$24,183	$31,641
Investment Income, Net	$13,820	$11,226	$12,205
Operating Expenses	$94,308	$177,534	$175,940
Net Income (Loss) Attributable to Parent	$-80,488	$-166,308	$-163,735
Operating Income (Loss)	$-94,308	$-177,534	$-175,940
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$-211	$225	$-250
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-80,699	$-166,083	$-163,985
Weighted Average Number of Shares Outstanding, Basic	31,469,328	38,462,600	50,358,629

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$74,293	$45,540	$154,682
Short-term Investments	$144,570	$267,281	$218,437
Long-term Investments	$47,683	$47,683	$5,108
Prepaid Expense and Other Assets, Current	$8,116	$20,076	$21,054
Operating Lease, Right-of-Use Asset	$154	$13	$370
Assets, Current	$226,979	$332,897	$394,173
Deferred Costs, Noncurrent	$2,732	$69	$41
Other Assets, Noncurrent	$126	$190	$134
Assets	$274,942	$333,169	$394,718
Operating Lease, Liability, Noncurrent	$14	$14	$33
Liabilities	$17,288	$25,945	$27,877
Common Stock, Value, Issued	$3	$4	$5
Additional Paid in Capital	$496,195	$711,847	$864,957
Retained Earnings (Accumulated Deficit)	$-238,333	$-404,641	$-497,854
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-211	$14	$-267
Stockholders' Equity Attributable to Parent	$257,654	$307,224	$366,841
Accounts Payable, Current	$3,782	$5,934	$2,217
Accrued Liabilities, Current	$13,330	$19,997	$25,309
Operating Lease, Liability, Current	$162	$14	$318
Liabilities, Current	$17,274	$25,945	$27,844
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	33,706,765	42,452,251	48,319,591

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-80,488	$-166,308	$-163,735
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-76,096	$-28,753	$41,917
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$74,293	$45,540	$57,778
Share-based Payment Arrangement, Noncash Expense	$3,208	$12,520	$19,088
Payments to Acquire Investments	—	$272,934	$319,925
Depreciation, Amortization and Accretion, Net	—	$-3,026	$-3,026
Proceeds from Sale, Maturity and Collection of Investments	—	$201,706	$247,620
Net Cash Provided by (Used in) Investing Activities	$-192,465	$-71,228	$-72,305
Proceeds from Issuance of Common Stock	—	$202,631	$260,733
Proceeds from Stock Options Exercised	$631	$502	$1,135
Payments of Stock Issuance Costs	$2,414	$70	$70
Net Cash Provided by (Used in) Financing Activities	$186,581	$203,063	$262,151
Increase (Decrease) in Prepaid Expense and Other Assets	$-1,464	$12,561	$7,223
Increase (Decrease) in Other Operating Assets	$20	$20	—
Increase (Decrease) in Accounts Payable, Trade	$-751	$2,141	$-1,843
Increase (Decrease) in Accrued Liabilities	$6,377	$6,667	$9,831
IncreaseDecreaseInOperatingLeaseLiability	$-2	$-21	$-31
Net Cash Provided by (Used in) Operating Activities	$-70,212	$-160,588	$-147,929

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("AVBP","financials")

Full statements spill as a table. For one cell: =jivedata("AVBP","Revenue") or =jivedata("AVBP","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.